Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development

Phio Pharmaceuticals Corp.

Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.
Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.
Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.
Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Robert Infarinato

VP, Strategic Development

PHIO · Phio Pharmaceuticals Corp.

Effective: 2025-06-06
Successor: Lisa Carson
Filed: Jun 12, 2025 23:59 UTC

Also effective June 6, 2025, Mr. Infarinato, who was previously the Company’s Chief Financial Officer, now serves as VP, Strategic Development of the Company.

Appointed

Lisa Carson

VP, Finance and Administration

PHIO · Phio Pharmaceuticals Corp.

Effective: 2025-06-06
Filed: Jun 12, 2025 23:59 UTC

designated Lisa Carson, VP, Finance and Administration of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of June 6, 2025.

Source: SEC EDGAR

accession 0001683168-25-004421

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.